{"id":249819,"date":"2025-08-05T00:00:00","date_gmt":"2025-08-05T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0007-2023-biopharma-biosimilars-access-reimbursement-payer\/"},"modified":"2026-03-31T10:25:30","modified_gmt":"2026-03-31T10:25:30","slug":"biosbi0007-2025-biopharma-biosimilars-access-reimbursement-payer-insights-landscape-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0007-2025-biopharma-biosimilars-access-reimbursement-payer-insights-landscape-us-eu\/","title":{"rendered":"Biosimilars – Access & Reimbursement – Payer Insights Landscape (US\/EU)"},"content":{"rendered":"

Biosimilar regulations and guidance have been defined, at least in draft form, in most the world\u2019s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA, which first implemented a development framework for biosimilars, but the degree of similarity and granularity varies by country. Payers play a significant role in defining the commercial success of biosimilars\u2014as well as their reference brands\u2014as they decide which products are granted formulary access and preferential reimbursement. As such, it is necessary for biosimilars developers and manufacturers of branded biologics to understand payers\u2019 perceptions and attitudes toward biosimilars, which factors influence payer decisions regarding biosimilars, and how these factors vary across different markets.<\/p>\n

Questions answered<\/strong><\/p>\n

\u2022 What does the country\u2019s biosimilar regulatory pathway dictate, and how does it differ from other markets?<\/div>\n
\u2022 Is automatic, pharmacy-level substitution permitted?<\/div>\n
\u2022 How are biosimilars priced and reimbursed?<\/div>\n
\u2022 Will payers\u2019 attitudes toward indication extrapolation restrict the use of biosimilars?<\/div>\n
\u2022 Will payers permit patients to continue current treatment with the reference brand or encourage switching to biosimilars?<\/div>\n
\u2022 What level of biosimilar discount do payers need to preferentially reimburse a biosimilar, and what formulary methods do payers expect to use to stimulate uptake of biosimilars at various price discounts?<\/div>\n
\u2022 Do payers expect availability of biosimilars to increase the total volume of the drug used?<\/div>\n
\u2022 What are the key strategies employed to drive biosimilar uptake?<\/div>\n
<\/div>\n
\n

Primary and secondary research:<\/strong> Primary market research includes survey of 60 U.S. payers and interviews with 10 EU5 KOLs; extensive secondary research conducted by subject matter experts<\/p>\n

Key drugs covered:\u00a0<\/strong>Admelog \/ Insulin Lispro Sanofi, Aranesp, Avastin, Basaglar \/ Abasaglar, Dupixent, Enbrel, Fasenra, Herceptin, Herzuma, Hulio, Humalog, Humira, Inflectra, Kanjinti, Kesimpta,\u00a0Neulasta, Neupogen, Nivestim \/ Nivestym, Nucala, Nyvepria, Ocrevus, Prolia, Remicade, Remsima, Rituxan \/ MabThera, Semglee, Stelara,\u00a0\u00a0Trazimera, Truxima, Tysabri, Udenyca, Zarzio \/ Zarxio, Ziextenzo<\/p>\n

Content highlights:\u00a0<\/strong>Reimbursement\u00a0and contracting, access and prescribing, opportunities and challenges for\u00a0emerging therapies<\/p>\n<\/div>\n

Product description<\/strong><\/p>\n

Clarivate\u2019s Biosimilars | Access & Reimbursement provides a detailed view of the regulatory pathways and payer policies for biosimilars in key markets so that clients can optimize their market access strategy and determine how to best position their brand to specific stakeholders.<\/p>\n

Biosimilars | Access & Reimbursement | Global Landscape provides an overview of the regulations, guidance, pricing, and reimbursement environment for biosimilars in the United States, Europe, Japan, and rest of world.<\/p>\n

Biosimilars | Access & Reimbursement | Payer Insights provides deep insights into the current and future market access environment for biosimilars in the United States and Europe and explores strategies used in formulary management and expectations on pricing.<\/p>\n","protected":false},"template":"","class_list":["post-249819","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249819\/revisions"}],"predecessor-version":[{"id":575758,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249819\/revisions\/575758"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}